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Summary
Id proteins are helix-loop-helix transcription factors that regulate tumor angiogenesis. In order to identify downstream
effectors of Id1 involved in the regulation of angiogenesis, we performed PCR-select subtractive hybridization on wild-
type and Id1 knockout mouse embryo fibroblasts (MEFs). Here we demonstrate that thrombospondin-1 (TSP-1), a potent
inhibitor of angiogenesis, is a target of transcriptional repression by Id1. We also show that Id1-null MEFs secrete an
inhibitor of endothelial cell migration, which is completely inactivated by depletion of TSP-1. Furthermore, in vivo studies
revealed decreased neovascularization in matrigel assays in Id1-null mice compared to their wild-type littermates. This
decrease was completely reversed by a TSP-1 neutralizing antibody. We conclude that TSP-1 is a major target for Id1
effects on angiogenesis.
Introduction progression, and/or metastasis of tumor xenografts in geneti-
cally altered mice (Lyden et al., 1999). Tumors that were able
Basic helix-loop-helix (bHLH) DNA binding proteins regulate to grow or metastasize in Id1- or Id3-deficient mice showed
tissue-specific transcription within multiple cell lineages (Mas- defects in vascularization and extensive necrosis. This defective
sari and Murre, 2000). The Id family of helix-loop-helix proteins angiogenesis was attributed to impaired VEGF-dependent re-
does not possess a basic DNA binding domain and inhibits cruitment of precursor endothelial cells from the bone marrow
lineage commitment within multiple cell types through seques- to the newly developing tumor vasculature (Lyden et al., 2001),
tration of bHLH transcription factors (reviewed in Norton, 2000). yet the precise mechanisms underlying this defective recruit-
Over the past several years, Id proteins have been implicated ment remain unclear. Several target genes for Id proteins have
in regulating a variety of cellular processes including cell growth, been identified largely based on the knowledge of promoters
activated by bHLH proteins; however, to date no systematicsenescence, differentiation, and neoplastic transformation (La-
sorella et al., 2001; Rivera and Murre, 2001; Zebedee and Hara, search for Id-regulated genes has been performed. Given the
variety of cellular processes affected by Id gene expression, we2001). More recently, evidence has been mounting to suggest
that Id1 and Id3 play a critical role in the regulation of angiogen- undertook an evaluation of Id target genes using a differential
gene expression profiling system with embryo fibroblasts fromesis during embryonic development and tumorigenesis (re-
viewed in Benezra et al., 2001). Lyden and colleagues have wild-type and Id1 knockout mice. Our studies have allowed us
to identify several Id1 target genes involved in diverse biologicaldemonstrated that at least one copy of the Id1 or Id3 gene
must be maintained in mice to prevent embryonic lethality and functions such as matrix remodeling, intracellular signaling path-
ways, and angiogenesis. One of the angiogenesis-related tar-associated defects in neuronal differentiation and angiogenesis
in the brain (Lyden et al., 1999). Moreover, loss of a single Id1 gets is the endogenous inhibitor of neovascularization, throm-
bospondin-1 (TSP-1).or Id3 allele has been shown to significantly impair the growth,
S I G N I F I C A N C E
Angiogenesis is critical for the development of all malignancies. Id transcription factors have been shown to regulate key steps in
tumor growth and metastasis due to their effects on angiogenesis. Thus, identification of Id transcriptional targets will be useful for
developing therapeutic interventions that disrupt Id-associated tumor growth and angiogenesis. Here we use a systematic genetic
approach to identify Id1 target genes and have identified the angiogenesis inhibitor thrombospondin-1 as being a critical target of
transcriptional repression by Id1. We show that mice null for Id1 have defects in angiogenesis which are largely due to increased
expression of thrombospondin-1, and therefore suggest that promotion of thrombospondin-1 anti-angiogenic activity in tumors with
increased Id gene expression may be a useful therapeutic intervention in such malignancies.
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TSP-1 is an extracellular matrix glycoprotein that inhibits higher levels in the vascular structures of Id1-null embryos as
tumor growth and metastases (Rodriguez-Manzaneque et al., determined by colocalization of the immunostaining for TSP-1
2001; Sheibani and Frazier, 1995; Streit et al., 1999; Volpert et and for the endothelial marker CD-31 (Figure 2). No obvious
al., 1998; Weinstat-Saslow et al., 1994), and was the first protein differences in the endothelial cell densities within individual ves-
to be recognized as a naturally occurring inhibitor of angiogen- sels could be detected when Id1/ versus Id1/ embryonic
esis (Good et al., 1990). TSP-1 has been shown to be a potent tissues were compared.
inhibitor of in vivo neovascularization and tumorigenesis. Tar-
geted overexpression of TSP-1 in mice suppresses wound heal- Id-1 repression of TSP-1 promoter activity
ing and tumorigenesis while the lack of functional TSP-1 results is independent of E boxes
in increased vascularization of selected tissues (Rodriguez- In order to determine whether Id1 effects on TSP-1 expression
Manzaneque et al., 2001; Stellmach et al., 1996; Streit et al., occurred at the transcriptional level, we evaluated reporter activ-
1999, 2000). In addition, several oncogenes have been demon- ities of the full-length murine TSP-1 promoter (2800 bp to48
strated to repress TSP-1 expression, including oncogenic ras bp) (Bornstein et al., 1990) and various promoter deletion mu-
(Rak et al., 2000), c-myc (Tikhonenko et al., 1996), v-src (Slack tants in the presence or absence of Id1 (Figure 3). Previous
and Bornstein, 1994), and c-jun (Mettouchi et al., 1994), thus studies of the murine TSP-1 promoter identified a serum-
providing a potential mechanism for activation of the angiogenic response element at 1210 bp that is critical for serum-regu-
switch in tumors. On the other hand, tumor suppressor proteins, lated expression of TSP-1, as well as overlapping Egr-1 and
such as p53 and PTEN, have been shown to maintain high, Sp1 sites necessary for the constitutive TSP-1 expression at
anti-angiogenic levels of TSP-1 (Dameron et al., 1994; Wen et the 70 bp region (Shingu and Bornstein, 1994); however, no
al., 2001), and the loss of functional wild-type p53 was found meaningful information has been available regarding the mouse
to result in an angiogenic switch in vitro due to the transcriptional TSP-1 promoter region between positions 2800 and 480.
inactivation of TSP-1 expression. Here we demonstrate that Id1, Since Id proteins function primarily via repression of E box and
a tumor-associated transcription factor, is a potent repressor Ets transcriptional activation sites (reviewed in Zebedee and
of TSP-1 transcription. We also demonstrate that upregulated Hara, 2001), we evaluated transcriptional activity of the mTSP-1
expression of TSP-1 leads to the suppression of angiogenesis in promoter and deletion mutants of the same promoter which
vivo in Id1 knockout mice and that this suppression is reversible carried varying numbers of E boxes and Ets sites for repression
upon antibody blockade of the functional TSP-1. We conclude by Id1. We observed a dose-dependent repression of the full-
that Id1 repression of TSP-1 is a major determinant of Id effects length mTSP-1 promoter by Id1 (Figure 3A). In addition, we
on tumor angiogenesis.
show continued TSP-1 repression by Id1 of the mutants con-
taining only the 160 bp to 48 bp fragment of the TSP-1
Results
promoter (Figure 3B). Since the 160 bp mutant contains no E
boxes or Ets sites and yet is repressible by Id1, we conclude thatTSP-1 is upregulated in Id1/ mouse embryo fibroblasts
either Id1 is functioning via yet uncharacterized DNA consensusIn order to identify downstream effectors of the helix-loop-helix
sites or is functioning through putative downstream effectorsprotein Id1, we performed suppression subtractive hybridization
to inhibit TSP-1 expression. Interestingly, we identified a strongon cDNAs from early-passage (P-3) Id1 wild-type (/) and Id1
region of transcriptional repression between 1120 bp andknockout (/) mouse embryo fibroblasts (MEFs). Forward and
1310 bp of the murine TSP-1 promoter, which has not beenreverse subtractions were repeated twice with two distinct pools
previously described; however, deletion of this region did notof Id1/ and Id1/ MEF cDNAs. The initial screening of clones
affect repression by Id1.using forward subtracted and reverse subtracted library probes
yielded over 125 cDNAs that were upregulated in Id1/ MEFs
TSP-1 is the key inhibitor of endothelial cell migration(i.e., repressed by Id1). Sequence analysis identified several
secreted by Id1-null MEFsclones that were likely to affect endothelial cell migration and
The in vitro endothelial cell migration assay provides a reproduc-possibly angiogenesis (Table 1). One of the isolated clones en-
ible and quantitative measurement of the pro- or anti-angiogeniccoded a 625 bp cDNA insert identical to a fragment of the
activity of compounds and consistently parallels angiogenic ef-murine TSP-1 gene with the exception of a 41 bp stretch within
fects observed in vivo (Bouck et al., 1996; Folkman and Klags-the matched sequences which was felt to represent differential
brun, 1987; Klagsbrun and D’Amore, 1991). In order to deter-splicing. Upregulation of the TSP-1 mRNA was confirmed by
mine whether Id1 regulation of thrombospondin expressionsemi-quantitative RT-PCR and Northern analysis of Id1/ and
affected angiogenesis, we tested conditioned media (CM) fromId1/ mRNAs (Figure 1). Quantitative analysis of the Northern
Id1/ and Id1/ MEFs for their ability to induce migration ofblots revealed a 3-fold increase in TSP-1 mRNA in Id / versus
both bovine adrenal capillary endothelial cells (BACECs) andId1/ MEFs. This change in mRNA level was reflected in the
human dermal microvascular endothelial cells (HDMECs) (Figurelevel of secreted TSP-1 protein in conditioned media from Id1/
4A and data not shown). CM from Id1/ MEFs were moderatelyMEFs, which was 3- to 5-fold greater than the level of TSP-1
angiogenic while CM from Id1/ MEFs failed to induce endothe-in conditioned media from Id1/ MEFs (Figure 4B).
lial cell migration over the background levels observed in the
presence of BSA. Neutralizing TSP-1 antibody fully relieved theEndothelial cell-associated expression of TSP-1
inhibition of endothelial cell chemotaxis by Id1/ CM in bothis elevated in Id1/ mouse embryos
BACECs and HDMECs to the levels observed in Id1/ CMIn order to determine whether in vivo expression of TSP-1 was
while isotype control antibody had no effect, suggesting thataltered in Id1/ mice, day E13.5 embryos were evaluated for
TSP-1 expression. We found that TSP-1 was expressed at impaired endothelial cell migration in the presence of Id1/ CM
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Table 1. Genes identified in PCR-Select screen for downstream targets of Id1
Clone Genbank Accession Number Function
Glutathione reductase XM_132691 Reduces reactive oxygen species
Fibulin-2 X75285 ECM protein, endostatin binding protein
Ser-thr kinase receptor binding protein AF096285 WD-domain protein involved in TGF signalling
Cathepsin B S69034 Lysosomal enzyme
FISP-12 M70642 ECM protein, promotes endothelial cell adhesion and migration
Filamin A (actin-binding protein 280) X53416 Couples integrins to cytoskeletal actin; assembles signalling complexes
for cell motility/proliferation
Thrombospondin XM_130459 ECM protein, potent inhibitor of angiogenesis
Lysyl oxidase L04262 Extracellular Cu-aminooxidase; collagen/elastin X-linking, incr. in cell
senescence; tumor suppressor fn.
Pro-alpha 2 (I) collagen AF004877 ECM protein, upregulated during cellular senescence
Cytochrome C oxidase L07096 Mitochondrial gene fn. in cellular oxidative phosphorylation; induced
by p53
beta-5 integrin AF022110 Forms heterodimers with alpha-v integrin, fn. in cell migration and
growth factor-induced angiogenesis
Inhibin beta-A M37482 Subunit of activin (TGF cytokine); involved in ALK receptor activation
Fibronectin X93167 ECM protein, binds integrins
Genes listed are among those which were found to be upregulated in Id1/ cells (i.e., repressed by Id1) using PCR-Select subtractive cloning. Listed genes
have been identified as possible regulators of tumor angiogenesis.
was largely due to increased levels of TSP-1 secretion. Western from Id1/ and Id1/ CM. We demonstrate decreased activity
of MMP-2 in CM from Id1/ MEFs (Figure 4C) consistent withblot analysis of CM from three independent experiments con-
firmed the elevated expression of TSP-1 in Id1/ CM versus the loss of MMP-2 expression noted previously in Id1/ mouse
embryos (Lyden et al., 1999). Conversely, we note increasedId1/ CM (Figure 4B). Since matrix metalloproteinases have
been shown to influence endothelial cell migration and the angi- gelatinase activity of an unidentified 120 kDa protein product
in CM from Id1/ MEFs.ogenic switch, we examined the function of metalloproteinases
Figure 1. Thrombospondin-1 is upregulated in Id1/ MEFs
A: Dot blot of subtraction libraries. A library of (Id / MEF cDNAs)  (Id1/ MEF cDNAs) is spotted in 1b. A library of (Id1/ MEF cDNAs)  (Id1/ cDNAs) is
spotted in 1c. Id1/ MEF cDNA is spotted in 2b. Id1/ MEF cDNA is spotted in 2c. Purified Id1 cDNAs are spotted in column a. Probe for dot blot is murine
TSP-1.
B: Northern analysis of murine TSP-1 and Id1 in Id1/ and Id1/ MEFs. Lower panel illustrates loading control on ethidium bromide-stained formaldehyde
gel.
C: Semiquantitative RT-PCR of mTSP-1 and GAPDH from Id1/ and Id1/ MEFs at P-3. M  φXHaeIII DNA size marker.
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Figure 2. Endothelial cells of Id/ embryos secrete higher TSP-1 levels in vivo
Immunostaining of Id1/ and Id1/ mouse embryos. Snap-frozen sections of Id/ embryos and their wild-type littermates were stained for TSP-1 (A, green
fluorescent label), and CD-31, to highlight endothelial structures (B, red fluorescent label) and analyzed by confocal microscopy. C shows a composite
image of A and B where colocalized staining appears yellow. Note increased intensity of green fluorescence (TSP-1) in Id/ embryo in A (TSP alone) and
C (composite images) while red fluorescence intensity (capillary structures, panels B) remains similar. The change in green fluorescence intensity is even
more obvious in the composite images at higher resolution (panels D). H&E sections are included for orientation (E).
Id1-null mice display defects in angiogenesis density in tumor xenografts formed by Lewis lung carcinoma
cells (Figure 6 and data not shown) was also lower in Id1-nulldue to elevated levels of secreted TSP-1
Our in vitro assays suggested that TSP-1 is a likely target mice versus wild-type controls (1.3-fold, p  0.01). Interest-
ingly, when the vessels were stained for vascular smooth musclethrough which Id1 exerts much of its effect on angiogenesis.
To assess the relevance of Id1-mediated TSP-1 regulation in cell (VSMC) actin, the number of CD31-positive vascular struc-
tures (mature or maturing vessels) was visibly higher in thevivo, we performed matrigel assays in Id1 wild-type and Id1
knockout mice. The animals received subcutaneous matrigel tumors harbored by wild-type mice versus Id1 knockout mice
(Figure 6), suggesting that endothelial-associated TSP-1 mayplugs containing bFGF to trigger angiogenesis. When neovascu-
larization was assessed in matrigel 10 days following injection, interfere with VSMC recruitment or, alternatively, block capillary
formation before VSMC recruitment and vessel maturation areId1/ mice had significantly lower angiogenic activity compared
to their wild-type littermates (Figure 5), consistent with earlier completed. Given the above data, we conclude that TSP-1 is
a transcriptional target of Id1 in vivo and a major effector of itsfindings (Lyden et al., 1999, 2001). Seeking a link between im-
paired angiogenesis and higher TSP-1 levels in Id1/ mice, role in angiogenesis.
the assays were repeated using matrigel plugs containing pro-
angiogenic bFGF  neutralizing TSP-1 antibody. Neutralization Discussion
of TSP-1 activity resulted in a dramatic 1.9-fold increase in
microvessel density in Id1/ mice in our matrigel studies versus Id genes have been implicated in the regulation of tumor angio-
genesis: Id knockout mice are resistant to tumor growth anda modest 0.5-fold increase in Id1/ mice, while isotype-
matched control antibody had no effect (Figure 5). Similar exper- metastasis due to impaired angiogenesis although the mecha-
nisms underlying the angiogenesis defects are only partiallyiments were performed using VEGF to stimulate angiogenesis
in matrigel assays. These data confirmed the lower angiogenic characterized (Lyden et al., 1999). Our data suggest that Id1
regulates tumor neovascularization via transcriptional repres-activity in Id1/ mice with increased angiogenic response noted
in the presence of neutralizing anti-TSP-1 antibody in Id1/ sion of the angiogenesis inhibitor TSP-1. These results indicate
that Id1 either acts indirectly on the mTSP-1 promoter or utilizesmice versus wild-type controls (data not shown). Microvascular
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Figure 3. Id1 is a repressor of the mTSP-1 promoter
A: Dose-dependent inhibition of mTSP-1 promoter activity by Id1. B  basal luciferase activity of 1 g of reporter construct. FL  promoter activity of 1 g
of full-length mTSP-1 promoter. Other data represent mTSP-1 promoter activity with addition of 0.1–1.0 g of Id1.
B: Promoter activity of deletion mutants of FL mTSP1 promoter (2800 bp–48 bp). Number of E boxes/Ets sites is depicted on the left. Id1 inhibition of
promoter activity of all mutants is depicted at the right where black bar is reporter activity alone and shaded bar is reporter activity 1 g of Id1. Note
continued Id1 repression with 160 bp–48 bp mutant.
a novel regulatory element for this class of HLH proteins. Indeed, regulation of TSP-1 may occur through differing mechanisms
in these species.previous studies have identified the 239 to 135 bp region
of the mTSP-1 promoter as being critical for c-jun-mediated Our data also show that TSP-1 is a target of Id1 repression
in vivo and a potent mediator of Id1-associated effects on angio-repression (Dejong et al., 1999). This repressive effect is indirect
and requires activation of WT1 and enhanced WT1 binding to genesis. We have shown that loss of Id1 expression in mice is
associated with inhibition of bFGF- and VEGF-induced angio-the mTSP-1 promoter. We have been able to identify a region
between 1310 and 1120 bp of the mTSP-1 promoter that genesis, which is reversed by inactivation of TSP-1 function.
Thus, impaired tumor growth and metastases in Id-null miceis strongly repressive in NIH3T3 cells under standard growth
conditions; however, a similar constitutively repressible region are at least in part due to the increase in active thrombospon-
din-1 and subsequent inhibition of tumor angiogenesis. Muchof the human TSP-1 promoter has not been identified to date.
While the possibility to restore TSP-1 promoter activity via such previous data supports the role of TSP-1 in inhibiting tumor
angiogenesis. Overexpression of TSP-1 in tumor xenografts hasan element might be of therapeutic use to inhibit inappropriate
angiogenesis, the small degree of homology between the human been shown to inhibit tumor cell growth in vivo in a variety of
tissue types (Bleuel et al., 1999; Sheibani and Frazier, 1995;and murine TSP-1 promoters suggests that the transcriptional
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Figure 4. Inhibition of endothelial cell migration
by Id1/ MEFs is due to increased activity of
thrombospondin-1
A: Endothelial cell migration assay. Human mi-
crovascular endothelial cells (HDMECs) were
stimulated to migrate up a gradient of pro-angi-
ogenic bFGF (10 ng/ml, clear bars) or media
conditioned by wild-type MEFs (/), or MEF’s
null for Id1 (/). Anti-TSP-1 neutralizing antibody
(10 g/ml) was added where indicated. Anti-
bodies alone had no effect on the basal endo-
thelial cell migration (BSA, hatched bars) and
effectively blocked TSP-1 inhibitory effect on
bFGF-induced chemotaxis (bFGF, black bars).
Gray bars show inhibition of bFGF-induced mi-
gration by TSP-1. Note significantly decreased
migration of endothelial cells in the presence of
CM from Id1/ MEFs versus Id1/MEFs. This differ-
ence is completely abrogated by neutralizing
TSP-1 antbody but not affected by nonspecific
control antibodies (mouse IgM). Bars marked
with * are significantly different from basal migra-
tion with BSA (p  0.003).
B: Western analysis of mTSP-1 expression in condi-
tioned media from Id1/ (/) and Id1/ (/)
MEFs.
C: Gelatinase activity of CM from Id1/ and
Id1/ MEFs. Controls for MMPs are included at
left. Positive gelatinase activity is noted by clear-
ing of coomassie-stained gelatin (white band).
Size markers are depicted at far left.
Streit et al., 1999; Volpert et al., 1998), while expression of demonstrated an increased incidence of osteosarcomas versus
mice lacking p53 alone. In addition, tumor xenografts fromTSP-1 has been inversely correlated with malignant progression
in breast and lung carcinomas and melanomas (Zabrenetzky et B16F10 melanoma grew faster and exhibited higher vascular
density in mice null for TSP-1, suggesting that TSP-1 can playal., 1994). Moreover, mice with a genetic susceptibility to breast
cancer showed decreased tumor formation in the presence of the role of modifier or “landscaper” gene to suppress tumor
growth (Lawler et al., 2001).a breast-specific TSP-1 transgene, while mice lacking TSP-1
showed increased tumor growth and progression (Rodriguez- Recent studies showed that defective tumor angiogenesis
in Id1/, Id3/ mice is due to altered host endothelial cellManzaneque et al., 2001). Thus, these data confirm the growth
autoinhibitory properties of TSP-1 expressed in tumors; con- recruitment and migration (Lyden et al., 2001). In these studies,
Id mutant mice were transplanted with wild-type bone marrowversely, these data also demonstrate that loss of TSP-1 from
tumors promotes malignant growth. In our system, however, (BM), and tumor angiogenesis was restored to baseline through
recruitment of exogenous BM-derived circulating endothelialwe are specifically interested in the effect of matrix-associated
TSP-1 expression since previous data suggest that it is the cell precursors. The authors suggest that recruitment of BM-
derived precursor cells is defective in Id mutant mice due tomatrix, rather than the tumor itself, that precludes tumor growth
in Id1 and/or Id3 knockout mice (Lyden et al., 1999). This is impaired induction of Id expression in response to VEGF; how-
ever, the identity of the downstream effectors related to VEGFsupported by experiments in which mice null for TSP-1 and p53
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Figure 5. Inhibition of angiogenesis in Id1-null mice is due to increased activity of TSP-1
A: Matrigel assay for angiogenesis in Id1/ mice versus Id1/ mice with and without neutralizing TSP-1 antibody (nTSP-1). Note significant decrease in
microvessel density in matrigel plugs from Id1/ animals. This inhibition of angiogenesis is abolished in the presence of neutralizing TSP-1 antibody (Id1/ 
nTSP-1).
B: Calculated percent microvessel area of matrigel plugs in Id1/ and Id1/ animals with and without neutralizing TSP-1 antibody. Significant inhibition of
angiogenesis is seen in Id1/ mice, which is reverted to near wild-type control levels with neutralizing TSP-1 antibody. Low levels of endogenous TSP-1 are
present in wild-type animals since neutralizing antibody increases microvessel area to some extent in these animals.
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Figure 6. Altered angiogenesis in tumor xenografts in Id1/ and Id1/ mice
Immunostaining of tumor xenografts in Id1/ and Id1/ mice. Lewis lung carcinoma cells were implanted into Id1/ and Id1/ mice and evaluated for
(A) vascular smooth muscle cell actin, (B) mTSP-1, and (C) CD31. D represents a merged image for all three panels where white is the composite overlap
for all immunofluorescent stains used. Note decrease in vascular smooth muscle cell actin staining in tumors grown in Id1/ mice.
induction of Id expression remained unclear. Here we also dem- induced endothelial cell apoptosis that precludes maturation
onstrate defects in VEGF-induced angiogenesis in Id1/ mice, (Guo et al., 1997; Jimenez et al., 2000).
which were reversed by inactivation of TSP-1. We therefore We also identified several other genes of interest in our
propose that recruitment of endothelial cells during tumor angio- screen for Id1 effectors (Table 1) that may be of relevance to
genesis may be altered in Id1- and/or Id3-null mice due to the defective tumor angiogenesis noted in Id1/Id3 knockout
increased TSP-1 expression in VEGF-responsive cells. This is mice. Among those was 5-integrin, whose repression by Id1
likely because a higher proportion of endothelial precursor cells may also contribute to Id effects on tumor angiogenesis. Recent
are positive for the TSP-1 anti-angiogenic receptor, CD36, com- data demonstrate enhanced growth of tumor xenografts as well
pared to fully differentiated microcapillary endothelial cells as enhanced pathological angiogenesis in mice lacking either
(Kuzu et al., 1993; Regezi et al., 1993). Thus, increased levels
3- or 5-integrin (Reynolds et al., 2002). Since 5-integrin
of TSP-1 in Id1-null mice may influence the recruitment of CD36- expression was upregulated in Id1/ MEFs, it is possible that
rich endothelial precursors along with causing apoptosis of the
increased 5-integrin expression may be an additional factor
CD36-positive mature microvascular cells of remodeling capil-
contributing to decreased tumor angiogenesis in these mice.
laries as previously noted (Jimenez et al., 2000). We also note
We await further information that may prove or disprove thethe effect of loss of Id1 on vessel maturation which may be
role of this gene as an Id1 downstream effector and its functionrelated to TSP-1 expression. In our experiments, tumors grown
in tumor-associated angiogenesis.in Id1/ mice showed fewer endothelial structures that ex-
Recent data have demonstrated a correlation between Idpressed vascular smooth muscle cell (VSMC) actin, a marker
gene expression and tumor invasiveness in a variety of humanof vascular maturity and stability. Earlier studies showed that
malignancies (reviewed in Lasorella et al., 2001); however, thequiescent, mature vessels are less susceptible to apoptosis by
precise genetic targets for Id genes in these tumors remainanti-angiogenic factors than remodeling ones (Benjamin, 2000;
unknown. Our data identify TSP-1, a potent inhibitor of angio-Folkman, 1995; Hanahan and Folkman, 1996; Volpert et al.,
genesis, as an important downstream effector of Id1 in mice2002). Thus, TSP-1 may perform an additional function in pre-
and a major regulator of Id1 effects on angiogenesis. Ongoingventing VSMC recruitment during the remodeling of tumor vas-
studies will identify other Id1 effectors, their role in angiogenesisculature, therefore rendering these vessels more susceptible
and tumor growth, and their relationship to TSP-1 in these pro-to injury. Alternatively, reduced staining for VSMC may reflect
dismantling of the capillaries in Id1-null mice due to TSP- cesses.
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Experimental procedures dia (basal media  0.1% BSA), and plated at 3  104 cells/well on the
bottom side of a gelatinized 5 m (for bovine cells) or 8 m (for human cells)
Generation and screening of subtracted cDNA library porous membrane (Nucleopore Corp., Pleasanton, California) in an inverted,
Id1/ mice were generated as previously described (Yan et al., 1997) and modified Boyden chamber (Neuroprobe Inc.) and incubated at 37	C for 2
are of identical genetic background to Id1/mice. Mouse embryo fibroblasts hr to allow attachment. The chambers were then reinverted, 50 l of test
(MEFs) at passage 3 (P-3) were prepared as previously described (Alani et sample was placed in the top wells, and the cells were allowed to migrate
al., 2001). Total cellular RNA was extracted using guanidinium isothiocya- toward the test samples for 4 hr at 37	C. TSP-1 was purified as previously
nate, and polyA RNA was prepared on an oligo dT column. Two micrograms described (Volpert et al., 1998) and used at a concentration of 5 nM. For
of each RNA was reverse transcribed and used as both driver and tester assays with neutralizing antibody, the A4.1 anti-TSP-1 monoclonal antibody
in forward and reverse subtractions as outlined in the PCR-Select cDNA (NeoMarkers) was added at 10–20 g/ml. Membranes were removed, fixed,
Subtraction Kit (Clontech). Each subtraction was repeated twice with two and stained (DiffQuick, Fisher), mounted on glass slides, and the number of
independent cell populations. Final pools of subtracted cDNAs were cloned cells migrating to the top side of the membrane in ten high-powered fields
into pBluescript SK (Stratagene). Differential screening of clones was per- were counted. Samples in each experiment were tested in quadruplicate
formed according to manufacturers recommendations (PCR-Select, Clon- and experiments were repeated at least three times. Statistical significance
tech). Clones which were differentially expressed were then sequenced and of the difference between sample means was determined using two-tailed
further evaluated on Northern blots. Student’s t test. Basal migration in the presence of 0.1% BSA was used as
a negative control, migration toward a known angiogenic stimulus (bFGF,
Northern analysis and semi-quantitative RT-PCR 10 ng/ml) as a positive control.
Total cellular RNA was prepared from P-3 MEFs as above, separated on a
1.2% agarose gel, and transferred to nitrocellulose membranes. Blots were Matrigel angiogenesis assays
probed with 32P-labeled probes encoding a full-length murine Id1 cDNA, Mice were injected subcutaneously with 0.75 ml Matrigel supplemented with
murine Tsp-1 (66–681 bp), and murine GAPDH, and quantified using a phos- 150 ng/ml basic fibroblast growth factor (bFGF) (R&D Systems) or VEGF
phorimager (Molecular Dynamics). Semi-quantitative RT-PCR was per- 5 g/ml as previously described (Passaniti et al., 1992). For assays with
formed as previously described (Jacobs et al., 1999) using the forward primer neutralizing antibody, the A4.1 anti-TSP-1 monoclonal antibody (NeoMark-
5
 gggctagagaaaccccccac 3
 and reverse primer 5
ccaaagggagaaagtcc 3
 ers) was added to the matrigel at 20 g/ml. Mice were sacrificed 10 days
to amplify up 66-681bp of murine TSP-1. after the Matrigel injection. Gels were recovered by dissection, fixed in PBS-
buffered 10% formalin containing 0.25% glutaraldeheyde, sectioned, and
Promoter analysis stained with Masson’s Trichrome. The Image-Pro analysis system was used
Plasmids possessing 2800 to 48 bp of the murine thrombospondin pro- to quantify the area occupied by vessels in the histological sections. The
moter driving a luciferase reporter gene were kindly provided (Paul Bornstein, mean vessel area/field from 10–20 fields/section/plug (X200 20 objective
University of Washington, Seattle, Washington). Deletion mutants were con- lens and 10 ocular lens: Zeiss Axioskop) was calculated and expressed
structed using PCR amplification of the regions of interest and KpnI/HindIII as mean percentage area occupied by blood vessels SEM. The experiment
cloning sites for insertion into the reporter plasmid. All mutants constructed was repeated twice. For fluorescent staining, Matrigel plugs were snap frozen
were sequenced in their entirety using standard techniques. pGL2-Basic in OCT compound, 5 m thick cryosections obtained, and fixed in cold
(Promega) expression plasmids were used as negative controls. NIH 3T3 acetone, 1:1 acetone/chloroform, rinsed in PBS, and blocked in 5% donkey
cells were cultured in DMEM 10% calf serum and plated into 35 mm dishes.
serum, 1% BSA. The slides were incubated overnight with rat anti-mouse
Cells at 60% confluency were transfected with 1 ug of reporter construct
CD31 antibody (PharMingen), washed, and re-blocked. PE-labeled anti-rat
and 0–1.0 g of EMSV-Id1 or EMSV plasmid using FuGENE 6 reagent
and FITC- or CyanTM- anti-hamster antibodies (Jackson Labs) were added
(Roche) according to the manufacturer’s protocol so that the total amount
in blocking solution for 1 hr (26	C), slides washed, and mounted in Mowiol
of DNA transfected was constant and totaled 2 g. Transfections were
(Fisher). Quantitative image analysis of digital images taken with Spot camera
normalized for efficiency using 0.01 ug of pRL (renilla luciferase plasmid).
under inverted fluorescent microscope was performed using MetaView soft-
Cells were harvested 48 hr after transfection and reporter activity was mea-
ware. The number of CD31-positive structures was counted in a minimum
sured using the Dual Luciferase (Promega) assay according to the manufac-
of five high-powered (100) fields. Statistical significance of the data was
turer’s recommendations.
evaluated using two-tailed Student’s t test.
Preparation of conditioned media
ZymographyConditioned media were prepared from P-3 MEFs in the folowing manner.
Samples were mixed 1:2 with sample buffer (62.5 mM Tris-CL, pH 6.8, 4%Cells were grown to 90% confluence in complete media then washed twice
SDS, 25% glycerol, and 0.01% Bromophenol Blue), and run at 100 voltswith Ca2/Mg2-free PBS and placed in either serum-free DMEM or serum-
through a gel (10% polyacrylamide [wt/vol], 0.1% SDS, 0.1% gelatin). Thefree PC-1 (Clonetics) media for 48 hr (DMEM) or 24 hr (PC-1). The protease
gel was then placed in 2.5% Triton X-100 to allow for renaturation of theinhibitor AEBSF was added to a final concentration of 0.5 mM and media
embedded proteins. Subsequently, the gel was placed in buffer (50 mMwere concentrated in a Centricon plus-20 (Millipore) with a 10 kDa molecular
Tris-Cl, pH 7.5, 200 mM NaCl, 5mM CaCl2, and 0.02% Brij-35) at 37	C forweight cutoff for 2–3 hr at 4	C. Final protein concentrations of CM were
16 hr to optimize metalloproteinase activity. The gel was stained for 1 hr inbrought to 5 mg/ml with basal media. To determine angioinhibitory activity,
40% methanol/10% acetic acid/0.5% (wt/vol) Coomassie brilliant blue G-250conditioned media were tested for their ability to block capillary endothelial
and then destained in the same buffer without Coomassie brilliant blue.cell migration induced by the known angiogenic factor basic fibroblast
Proteinase activity was subsequently inferred by the presence of clear bandsgrowth factor (bFGF).
which appeared against a blue background. Molecular weights of the protein-
ases were determined by comparison to protein molecular weight standardsEndothelial cell migration assays
(Bio-Rad) and metalloprotease controls (Chemicon International, Temecula,Bovine adrenal capillary endothelial cells were a kind gift of Dr. Judah Folk-
California). Control proteins were run at 5 ng/lane and were of human originman (Children’s Hospital, Harvard Medical School) and grown in Dulbecco’s
(MMP-2 and -9 were purified human proteins, and MMP-7 was humanmodified Eagle’s medium supplemented with 10% donor calf serum (Flow
recombinant).Laboratories, McLean, Virginia) with 1% endothelial cell mitogen (Biomedical
Technologies, Inc., Stoughton, Massachusetts) and used between passages
Western blotting14 and 15. Human dermal microvascular endothelial cells from Clonetics
Conditioned media, collected as described, were loaded on 6% SDS-PAGECell Systems (San Diego, California) were grown in basal endothelial cell
(7.5 ug total protein/lane) along with purified human TSP-1 (positive control)growth medium (MDCB131, GIBCO) with the supplement bullet kit
and transferred to PVDF membrane (Amersham). The blots were probed with(Clonetics) and 5% fetal bovine serum, and used at passage 9. Migrations
anti-TSP monoclonal IgM (NeoMarkers), developed with HRP-conjugatedwere performed as described previously (Polverini et al., 1991). Endothelial
cells were serum-starved overnight, harvested, resuspended in control me- secondary antibodies (RBI), and visualized by exposure with X-ray film.
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Dameron, K.M., Volpert, O.V., Tainsky, M.A., and Bouck, N. (1994). ControlImmunostaining of tissue specimens
of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Sci-Mouse embryos, tumor xenografts and Matrigel plugs were excized, snap-
ence 265, 1582–1584.frozen in Tissue-Tek OCT (Sakura), and kept at 8	C. Five micrometer thick
sections were prepared immediately before staining. The sections were fixed Dejong, V., Degeorges, A., Filleur, S., Ait-Si-Ali, S., Mettouchi, A., Bornstein,
by consecutive treatments with ice-cold Acetone, Acetone/Chloroform mix P., Binetruy, B., and Cabon, F. (1999). The Wilms’ tumor gene product
(1:1), and Acetone. Endogenous biotin and avidin were blocked using the represses the transcription of thrombospondin 1 in response to overexpres-
Blocking kit from Vector Labs, as recommended by manufacturer, followed sion of c-Jun. Oncogene 18, 3143–3151.
by 1 hr incubation in MOM blocking solution (Ibid) containing Mouse Immu-
Folkman, J. (1995). Seminars in medicine of the Beth Israel Hospital, Boston.noglobulin Blocking Reagent. For colocalization of CD31 and TSP-1, the
Clinical applications of research on angiogenesis. N. Engl. J. Med. 333,sections were then washed twice and incubated for 5 min in MOM diluent
1757–1763.(protein block), and incubated 30 min at room temperature with primary
antibodies in MOM at the following dilutions: anti-CD31 rat anti-mouse poly- Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. Science 235,
clonal (Santa Cruz) at 1:125 and anti-TSP-1 mouse monoclonal IgM (Neo- 442–447.
Markers) at 1:100. The sections were rinsed twice for 2 min in PBS and
Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S.,exposed for 15 min (room temperature) to the following dilutions secondary
Frazier, W.A., and Bouck, N.P. (1990). A tumor suppressor-dependent inhibi-of the antibodies in MOM: donkey anti-rat RhodaminX conjugated (Jackson
tor of angiogenesis is immunologically and functionally indistinguishableLabs) 1:200 and biotinylated anti-mouse AB (MOM kit, Vector Labs) 1:250.
from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624–The samples were then washed in PBS and incubated for 5 min with Fluores-
6628.
cein Avidin D (Vector Labs) in PBS at 20 ug/ml. To visualize vascular smooth
muscle, sections stained for CD31/TSP-1 were washed three times for 3 Guo, N., Krutzsch, H.C., Inman, J.K., and Roberts, D.D. (1997). Thrombo-
spondin 1 and type I repeat peptides of thrombospondin 1 specifically inducemin each in PBS and endogenous biotin/avidin and mouse IgG re-blocked
apoptosis of endothelial cells. Cancer Res. 57, 1735–1742.as above. Tissue sections were exposed for 30 min (room temperature) to
mouse monoclonal IgG against vascular smooth muscle actin at 1:200 dilu-
Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms
tion in MOM, washed two times for two min each. Biotinylated anti-mouse
of the angiogenic switch during tumorigenesis. Cell 86, 353–364.
antibodies (MOM kit) were applied as above, followed by 3  3 min washes
in PBS and incubation with Streptavidin Cy5 (Jackson Labs, 1:1000) in PBS Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A., and van Lohuizen,
(15 min at room temperature). The slides were mounted and fluorescent M. (1999). The oncogene and Polycomb-group gene bmi-1 regulates cell
proliferation and senescence through the ink4a locus. Nature 397, 164–168.images analyzed by confocal microscopy.
Jimenez, B., Volpert, O.V., Crawford, S.E., Febbraio, M., Silverstein, R.L.,Tumor xenograft assay
and Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of
2.0  106 Lewis lung carcinoma cells were injected subcutaneously into the neovascularization by thrombospondin-1. Nat. Med. 6, 41–48.
flank of Id1/ and wild-type control mice. Mice were observed on a daily
basis and tumor measurements were taken 3/week. Tumors were excised Klagsbrun, M., and D’Amore, P.A. (1991). Regulators of angiogenesis. Annu.
Rev. Physiol. 53, 217–239.after 21 days and formalin fixed or snap frozen in Tissue-Tek OCT (Sakura)
for histologic analysis.
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